Dura mater mitral and tricuspid bioprostheses: 30 years of follow-up

Abstract

The dura mater bioprosthesis played an important role in the treatment of patients with mitral and tricuspid valve disease. The low rate of thromboembolism and the long period of follow-up without evidence of valve dysfunction, which occurred for several of our patients, are important characteristics of these bioprosthesis.

Reflexões sobre a durabilidade de 24 anos de uma bioprótese IMC/Braile de pericárdio bovino em posição tricúspide isolada

“…In a period of more than 30 years at the Mayo Clinic, 333 surgical patients received biological prostheses and 45 received mechanical prostheses for surgical treatment of Ebstein Anomaly and, a comparative study concluded that the presence of a bioprosthesis is an independent predictor of increased survival [12]. Puig et al reported three patients with tricuspid insufficiency who underwent valve replacement with homologous dura mater cardiac bioprostheses glycerol-preserved (Two patients were well 28 and 27 years later, and the third was lost to follow-up after 20 years) [13,14]. These reports strongly suggest the good results of isolated tricuspid valve bioprosthesis.…”

Brazilian Pioneers in Artificial Organs and Heart Surgery

“…When use of dura mater valves was discontinued, 3000 patients had gotten this implant, and results were very good when compared to other available valves (6).…”